Form 4: Macrogenics Director Scott Jackson Trades Shares

Macrogenics Inc. reports director Scott Jackson's transactions involving restricted stock units and stock options.

Summary

• Director Scott Thomas Jackson reported transactions on May 18, 2026, and May 19, 2026.
• On May 18, 2026, 3,750 restricted stock units (RSUs) vested, which were acquired by Jackson.
• These RSUs represent a contingent right to receive one share of Macrogenics Inc. common stock.
• On May 19, 2026, an additional 3,750 RSUs were acquired, scheduled to vest one year after the grant date or the day prior to the next annual meeting, if earlier.
• Also on May 19, 2026, Jackson acquired a stock option to buy 22,000 shares of common stock at an exercise price of $4.52.
• This stock option vests and becomes exercisable in monthly increments starting one month from the grant date, over a 12-month period.
• Following these transactions, Jackson beneficially owns 14,750 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily details routine insider equity transactions rather than significant financial performance or strategic shifts.

Positives

• Director Scott Jackson acquired 3,750 vested restricted stock units on May 18, 2026.
• Director Scott Jackson acquired 3,750 additional restricted stock units on May 19, 2026, indicating continued equity incentive.
• Director Scott Jackson acquired a stock option for 22,000 shares, demonstrating potential future upside and alignment with company performance.

Negatives

• The filing does not explicitly detail any negative financial performance or operational setbacks.

Risks

• The vesting schedule for the newly acquired RSUs is tied to the next annual meeting or one year from grant, introducing a time-based risk for immediate access to shares.
• The stock option has a vesting period of 12 months, meaning the shares are not immediately available for sale.
• The exercise price of the stock option is $4.52, meaning the stock price needs to exceed this level for the option to be profitable.

Future Outlook

The filing does not contain forward-looking statements or guidance. The details pertain to past transactions and vesting schedules for equity awards.

Industry Context

StockSavvy.ai notes that insider transactions, such as those reported by Macrogenics Inc. director Scott Jackson, are common in the biotechnology sector as a means of executive compensation and incentive alignment. The acquisition of stock options and RSUs is standard practice for retaining and motivating key personnel in companies focused on long-term research and development.

Stakeholder Impact

• Shareholders: The transactions indicate continued equity ownership and incentive alignment by a director, which can be viewed positively for long-term shareholder value.
• Employees: The structure of equity awards for management is a common practice that can influence overall employee morale and retention.
• Management: The acquisition of stock options and RSUs provides potential financial upside for the director, contingent on company performance and vesting schedules.

Next Steps

• The acquired stock option will vest and become exercisable in monthly increments over 12 months.
• The acquired RSUs will vest one year after the grant date or the day prior to the next annual meeting, if earlier.

Key Dates

Keywords

Macrogenics Inc., MGNX, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Transactions, Beneficial Ownership, Equity Awards, SEC Filing